联合疗法
医学
封锁
癌症研究
免疫系统
CTL公司*
药理学
环磷酰胺
体内
趋化因子
免疫学
细胞毒性T细胞
内科学
化疗
受体
化学
CD8型
体外
生物
生物技术
生物化学
作者
Yuichi Iida,Nanae Harashima,Takanobu Motoshima,Yoshihiro Komohara,Masatoshi Eto,Mamoru Harada
出处
期刊:Cancer Science
[Wiley]
日期:2017-08-08
卷期号:108 (10): 1974-1984
被引量:42
摘要
Immune checkpoint blockade is a promising anticancer therapy, but must be used in combination with other anticancer therapies to increase its therapeutic efficacy. Cyclophosphamide ( CP ) is a chemotherapeutic drug that shows immune‐modulating effects. In this study, we examined the effect of CP on anti‐ CTL ‐associated protein 4 ( CTLA ‐4) blockade therapy in two mouse tumor models. Drastic tumor regression was observed in the CT 26 colon carcinoma model after i.p. injection of CP (100 mg/kg) followed by anti‐ CTLA ‐4 antibody. However, administration in the reverse order increased apoptosis in tumor‐specific CD 8 + T cells. In the RENCA renal carcinoma model, the antitumor effect of combination therapy was marginal and the tumor‐bearing state reduced body weight with an increased serum level of interleukin‐6. Interestingly, although CP monotherapy increased myeloid‐derived suppressor cells ( MDSC s) in the spleens of both models, subsequent anti‐ CTLA ‐4 therapy increased MDSC s only in RENCA ‐bearing mice. Additionally, the serum levels of chemokine ligand 2 and C‐X‐C motif chemokine 10 were increased by the combination therapy only in RENCA ‐bearing mice and in vivo depletion of Gr‐1 + cells augmented the antitumor effect to some degree. These results reveal a contrasting effect of CP on anti‐ CTLA ‐4 therapy between the two mouse tumor models. Cyclophosphamide augments the antitumor effect of anti‐ CTLA ‐4 therapy in CT 26‐bearing hosts, whereas CP after anti‐ CTLA ‐4 therapy attenuates this effect through induction of apoptosis in tumor‐reactive T cells. Alternatively, CP ‐induced MDSC s can be increased by anti‐ CTLA ‐4 therapy only in RENCA ‐bearing hosts with an elevated level of interleukin‐6.
科研通智能强力驱动
Strongly Powered by AbleSci AI